Anti-IL-6 receptor antibody treatment for severe COVID-19 and the potential implication of IL-6 gene polymorphisms in novel coronavirus pneumonia

被引：48
|
作者：
Ulhaq, Zulvikar Syambani [1 ]
Soraya, Gita Vita [2 ]
机构：
[1] Maulana Malik Ibrahim Islamic State Univ Malang, Dept Biochem, Fac Med & Hlth Sci, Batu 65151, East Java, Indonesia
[2] Hasanuddin Univ, Dept Biochem, Fac Med, Makassar 90245, South Sulawesi, Indonesia
来源：
MEDICINA CLINICA | 2020年 / 155卷 / 12期
关键词：
OFF-LABEL USE; TOCILIZUMAB; INTERLEUKIN-6;
D O I：
10.1016/j.medcli.2020.07.002
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：548 / 556
页数：9
相关论文
共 50 条
  • [1] Is IL-6 the Right Target in COVID-19 Severe Pneumonia?
    Blot, Mathieu
    Bourredjem, Abderrahmane
    Binquet, Christine
    Piroth, Lionel
    Quenot, Jean-Pierre
    Charles, Pierre-Emmanuel
    Aptel, Francois
    Prin, Sebastien
    Andreu, Pascal
    Labruyere, Marie
    Dargent, Auguste
    Nguyen, Maxime
    Bouhemad, Belaid
    Georges, Marjolaine
    Bonniaud, Philippe
    Beltramo, Guillaume
    Buisson, Marielle
    Bonnotte, Bernard
    Bielefeld, Philip
    Barben, Jeremy
    Putot, Alain
    Monier, Serge
    Large, Audrey
    Mouries-Martin, Suzanne
    Devilliers, Herve
    Chavanet, Pascal
    Guilhem, Alexandre
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (01) : 139 - 140
  • [2] Anti-IL-6 receptor antibody treatment improves interstitial lung diseases in IL-6 transgenic mice
    Sugamata, Y
    Nakahara, H
    Katsume, A
    Sugimoto, M
    Yoshizaki, K
    Nishimoto, N
    JOURNAL OF LEUKOCYTE BIOLOGY, 2001, : 81 - 81
  • [3] Anti-IL-6 receptor antibody increases blood IL-6 level via the blockade of IL-6 clearance, but not via the induction of IL-6 production
    Uchiyama, Yasushi
    Yoshida, Hiroto
    Koike, Nobuo
    Hayakawa, Naohiko
    Sugita, Atsuko
    Nishimura, Takashi
    Mihara, Masahiko
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2008, 8 (11) : 1595 - 1601
  • [4] Anti-IL-6 Antibodies against COVID-19?
    Meinrenken, Susanne
    PNEUMOLOGIE, 2021, 75 (05):
  • [5] Efficacy of a Recombinant Humanized Anti-IL-6 Receptor Monoclonal Antibody Compared to Hemoperfusion in Severe COVID-19 Pneumonia: Ambispective Cohort Study
    Thammavaranucupt, Kanin
    Jayanama, Kulapong
    Spanuchart, Ittikorn
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 330 - 330
  • [6] Increase in serum levels of IL-6 and soluble IL-6 receptor after anti-IL-6 receptor antibody therapy in patients with rheumatoid arthritis
    Nishimoto, N
    Terao, K
    Kakehi, T
    Kishimoto, T
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S109 - S110
  • [7] ANALYSIS OF INTERLEUKIN 6 (IL-6)/IL-6 RECEPTOR SYSTEM USING MONOCLONAL ANTI-IL-6 ANTIBODIES
    SHIMAMURA, T
    TAKI, S
    HONDA, H
    YOKOTA, M
    ITO, S
    TAKAHARA, Y
    MOLECULAR IMMUNOLOGY, 1991, 28 (11) : 1155 - 1161
  • [8] The role of IL-6 in coronavirus, especially in COVID-19
    Wang, Xinyi
    Tang, Guozheng
    Liu, Yuchen
    Zhang, Lizhi
    Chen, Bangjie
    Han, Yanxun
    Fu, Ziyue
    Wang, Liuning
    Hu, Guangzhi
    Ma, Qing
    Sheng, Shuyan
    Wang, Jianpeng
    Hu, Xinyang
    Shao, Song
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [9] Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody
    Kazuyuki Yoshizaki
    Norihiro Nishimoto
    Masahiro Mihara
    Tadamitsu Kishimoto
    Springer Seminars in Immunopathology, 1998, 20 : 247 - 259
  • [10] Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody
    Yoshizaki, K
    Nishimoto, N
    Mihara, M
    Kishimoto, T
    SPRINGER SEMINARS IN IMMUNOPATHOLOGY, 1998, 20 (1-2): : 247 - 259
12345